Why the study?
How did the introduction of NOACs affect the use of oral anticoagulants in patients with AF and very high thromboembolic risk?
How did the introduction of NOACs affect the use of oral anticoagulants in patients with AF and very high thromboembolic risk?
Answers are grounded in this paper and cite their sources.
The introduction of NOACs significantly shifted prescribing patterns in very high-risk AF patients, reducing VKA and antiplatelet therapy use, though certain high-risk subgroups remain undertreated.
-VASc scores were calculated for all patients. The treatment with oral anticoagulants was compared in the entire population over 2004-2011 and 2012-2019. In this study, a fifth of patients were not treated with OAC. Most patients hospitalised in the years 2012-2019 were treated with OAC. The predictors of not using OAC turned out to be: age of >74 years, heart failure, cancer, paroxysmal AF, and acute coronary syndrome (ACS) or elective coronary angiography/percutaneous coronary intervention (PCI) as a reason for hospitalisation. The introduction of NOAC was associated with a decline in the use of VKA (from 62% to 19.1%) and APT (from 29.1% to 1.3%). This study outlines reasons to initiate OAC treatment in very high-risk patients in clinical practice.
No takes yet. Share an insight, caveat, or question.
Bielecka et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: